Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $138.00 at BMO Capital Markets

Neurocrine Biosciences (NASDAQ:NBIX) had its price target upped by BMO Capital Markets from $129.00 to $138.00 in a report issued on Thursday, Benzinga reports. BMO Capital Markets currently has a market perform rating on the stock.

NBIX has been the topic of a number of other research reports. StockNews.com upgraded shares of Neurocrine Biosciences from a buy rating to a strong-buy rating in a research report on Thursday, February 8th. Wells Fargo & Company raised shares of Neurocrine Biosciences from an equal weight rating to an overweight rating and raised their price objective for the stock from $140.00 to $170.00 in a research report on Wednesday, April 24th. The Goldman Sachs Group upped their price target on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a buy rating in a research note on Thursday, January 25th. Mizuho upped their price objective on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a neutral rating in a report on Thursday, February 8th. Finally, Barclays lifted their price objective on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the company an overweight rating in a report on Tuesday, January 23rd. Six analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $147.88.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $140.71 on Thursday. Neurocrine Biosciences has a one year low of $89.04 and a one year high of $148.37. The company has a market cap of $14.16 billion, a price-to-earnings ratio of 38.76 and a beta of 0.28. The firm has a 50 day simple moving average of $137.37 and a 200 day simple moving average of $129.00.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.31. The company had revenue of $515.20 million for the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. Neurocrine Biosciences’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same quarter last year, the business posted $0.88 EPS. As a group, analysts expect that Neurocrine Biosciences will post 4.78 EPS for the current year.

Insider Transactions at Neurocrine Biosciences

In other news, CEO Kevin Charles Gorman sold 3,040 shares of the firm’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $142.18, for a total transaction of $432,227.20. Following the sale, the chief executive officer now owns 504,919 shares in the company, valued at approximately $71,789,383.42. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 3,040 shares of the company’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $142.18, for a total transaction of $432,227.20. Following the completion of the transaction, the chief executive officer now owns 504,919 shares of the company’s stock, valued at approximately $71,789,383.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David W. Boyer sold 456 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $141.96, for a total value of $64,733.76. Following the transaction, the insider now directly owns 4,894 shares in the company, valued at $694,752.24. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 181,547 shares of company stock valued at $25,039,887. 4.30% of the stock is owned by corporate insiders.

Institutional Trading of Neurocrine Biosciences

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Neurocrine Biosciences by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 9,710,328 shares of the company’s stock valued at $1,279,433,000 after acquiring an additional 150,485 shares during the period. DSM Capital Partners LLC raised its holdings in Neurocrine Biosciences by 15.4% during the 3rd quarter. DSM Capital Partners LLC now owns 1,224,017 shares of the company’s stock valued at $137,702,000 after buying an additional 163,747 shares during the period. Brown Advisory Inc. lifted its position in Neurocrine Biosciences by 2.2% in the fourth quarter. Brown Advisory Inc. now owns 1,113,413 shares of the company’s stock worth $146,703,000 after buying an additional 23,831 shares during the last quarter. Braidwell LP boosted its stake in Neurocrine Biosciences by 3.7% during the third quarter. Braidwell LP now owns 968,024 shares of the company’s stock worth $108,903,000 after buying an additional 34,662 shares during the period. Finally, Los Angeles Capital Management LLC increased its position in Neurocrine Biosciences by 66.0% during the fourth quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock valued at $121,007,000 after acquiring an additional 364,986 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.